Expanding Access to HAART Saves Millions in Health Care and Productivity Costs (Dr. Julio Montaner, BC-CfE)
A study published in The Lancet HIV by the BC Centre for Excellence in HIV/AIDS (BC-CfE) shows expanding Treatment as Prevention® (TasP®) could save up to $66.5 million over the next 25 years, compared with a scenario with reduced access to antiretroviral medication. The study finds expanded access to highly active antiretroviral therapy (HAART) has more than offset the additional costs of treatment, resulting in improved health outcomes and cost-savings.
Savings are due to reduced hospitalization costs, productivity gains and averted HIV infectio ns through the implementation of TasP®. The expansion of TasP® in British Columbia, with support from the provincial government, has resulted in decreased HIV morbidity and mortality, as well as a reduction in new HIV cases. BC is the only province in Canada to have implemented TasP® and has had the greatest reductions in HIV incidence since combination antiretroviral therapy was introduced.
“These findings indicate Treatment as Prevention® could help to ensure greater sustainability of the Canadian health care system, if implemented on a national scale,” said Dr. Julio Montaner, Director of the BC-CfE. “At the global level, providing antiretroviral medication to those affected by HIV and AIDS could avert untold rates of illness, including in already resource-starved nations.”
Global News Wire reports
Dr. Scott MacDonald, Providence Crosstown Clinic